Articles from Axoft

Axoft, a neurotechnology company, today announced it has raised an oversubscribed $55 million Series A led by C.P. Group Innovation. Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment and Gaorong Ventures also participated in the round. With more than $60 million in total funding raised, Axoft will use the capital to expand its current clinical trials globally and progress U.S. regulatory approval of its implantable Brain-Computer Interfaces (iBCIs), which have already demonstrated the ability to safely decode brain signals, and offer a path for improving the standard of care for prognosis and communication in disorders of consciousness. Axoft will also use the capital to build a good manufacturing practice (GMP) facility to mass produce its iBCIs.

Axoft, a neurotechnology company, today announced the availability of its novel, ultra-soft materials for purchase by research and industrial organizations for research and development applications. Named Fleuron™, the material is designed to improve implantable Brain-Computer Interfaces (iBCIs) by providing superior biocompatibility, and significantly reducing tissue scarring and lead migration over time. The material was recently used in Axoft’s first-in-human clinical study, which marked the first time this type of bio-inspired material was authorized for human use and demonstrated that Fleuron passed the required ISO-10993 compatibility standards. In addition to Fleuron’s commercial launch, Axoft announced that it has secured an exclusive license agreement with Stanford University, which protects core aspects of the technology.

Axoft, a neurotechnology company, today announced preliminary results from its first-in-human clinical study, FINESSE, which began just two and a half years after the company’s seed funding round and was designed to show that Axoft’s implantable brain computer interfaces (iBCIs) can safely decode brain signals. The iBCIs in the study are made using Axoft’s novel Fleuron™ material, which is 10,000x softer than the polyimide used in existing iBCIs, offers superior biocompatibility, and significantly reduces tissue scarring and lead migration over time. In addition to the study results, Axoft announced a new research article that demonstrates how Fleuron can improve iBCI bandwidth, stability and access to deep brain regions in clinical settings.

Axoft, a neurotechnology company, today announced the approval of its first-in-human clinical study, which will take place in early 2025 at The Panama Clinic. The study will demonstrate the usability of Axoft’s novel soft materials that mimic the mechanical properties of brain tissue and are tailored to improve the stability of the tissue-electronics interface for implantable Brain-Computer Interfaces (iBCIs). Axoft’s study with The Panama Clinic marks the first time this type of bio-inspired material is authorized for human use.